Emmanuelle Schindler
Assistant Professor of Neurology and Medical Director of the Headache Center of Excellence at the West Haven VA Medical Center, Yale School of Medicine
Data updated
Research Footprint
Emmanuelle Schindler appears in 8 tracked papers (2015–2025), most studied alongside Psilocybin, LSD and Ayahuasca, across Headache Disorders (Cluster & Migraine), Chronic Pain and Safety & Risk Management.
Most-cited paper: Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin (133 citations).
Frequent co-authors: Christopher Gottschalk, Deepak Cyril D’Souza and Brian Pittman.
Background & Research
Emmanuelle Schindler, MD, PhD, is a neurologist and headache specialist at Yale School of Medicine with a research focus on cluster headache, migraine, and post-traumatic headache. Her work bridges psychedelic pharmacology and headache medicine, and she has led several exploratory and randomized clinical studies of psilocybin in headache disorders. Yale describes her as an active researcher investigating how limited dosing of psilocybin may help manage headache disorders.
Key Impact
She is a leading clinical researcher studying psilocybin and other classic psychedelics as potential treatments for migraine and cluster headache, helping establish human evidence in a highly underserved area of headache medicine.
Collaboration Network
6 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Emmanuelle Schindler is associated with.
Yale School of Medicine Center for Brain Mind Health
academicA research center within Yale School of Medicine focused on understanding the neuroscience of consciousness, mental health disorders, and the mechanisms of psychoactive substances. The Center for Brain and Mind Health bridges psychiatry and neuroscience to advance knowledge of brain-mind relationships and explore novel therapeutic approaches including psychedelic-assisted treatment at Yale.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →International Society for Research on Psychedelics
The International Society for Research on Psychedelics (ISRP) is a professional scientific society that connects researchers across disciplines to advance rigorous psychedelic science, collaboration, and dissemination.
View stakeholder →